THORACOSCOPIC LEFT ATRIAL APPENDAGE AMPUTATION CAN BE AN ALTERNATIVE TO ENDOVASCULAR OCCLUSION-Reference-Cited by-同舟云学术

THORACOSCOPIC LEFT ATRIAL APPENDAGE AMPUTATION CAN BE AN ALTERNATIVE TO ENDOVASCULAR OCCLUSION

Published:2024-03-29 Issue:1 Volume:13 Page:116-121
ISSN:2587-9537
Container-title:Complex Issues of Cardiovascular Diseases
language:
Short-container-title:Kompleks. probl. serdečno-sosud. zabol.

Author:

Khalimov Zakir Z.¹^ORCID,Mamchur Sergey E.¹^ORCID,Mamchur Irina N.¹^ORCID,Bokhan Nikita S.¹^ORCID,Kozyrin Kirill A.²^ORCID,Ivanova Anna V.¹^ORCID

Affiliation:

1. Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”

2. Federal State Budgetary Institution “A.V. Vishnevsky National Medical Research Center for Surgery” of the Ministry of Health of the Russian Federation

Abstract

HighlightsWe present a clinical case of a patient with atrial fibrillation and a high bleeding risk according to HAS-BLED bleeding risk score who underwent thoracoscopic left atrial appendage (LAA) occluder implantation due to lack of endovascular access. Thoracoscopic amputation of LAA also can be performed in cases where an endovascular access cannot be achieved due to occlusion of the inferior vena cava or thrombosis of LAA. However, it is necessary to monitor the condition of the stump when conducting thoracoscopic amputation of LAA, and stop anticoagulation therapy only in case of non-embologenic stump. AbstractAtrial fibrillation is the most common rhythm disorder that can be conservatively treated using antiarrhythmic therapy, and anticoagulants can be used to prevent thromboembolic complications. However, prolonged use of anticoagulants is complicated by the risk of bleeding. Left atrial appendage (LAA) occluder implantation is an alternative way of preventing of thromboembolic and hemorrhagic complications. The article presents a clinical case of thoracoscopic LAA amputation after unsuccessful endovascular LAA occluder implantation in the patient with the inferior vena cava occlusion.

Publisher

NII KPSSZ

Reference10 articles.

1. Mamchur S.E., Gorbunova E.V., Scherbinina D.A., Romanova M.P. Prevention of thromboembolic complications after atrial fibrillation cat heter ablation using dabigatran. Complex Issues of Cardiovascular Diseases. 2014;(1):59-66. doi:10.17802/2306-1278-2014-1-59-66. (In Russian)

2. Jame S., Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020;106 (1):10-17. doi: 10.1136/heartjnl-2019-314898.

3. Osadchiy A.M., Agarkov M.V., Vlasenko S.V., Stovpyuk O.F., Pavlova N.E., Mamaeva O.P., Miller J.V., Kamenev A.V., Gureev S.V., Lebedeva S.V., Shcherbak S.G., Lebedev D.S. Left atrial appendage occluder implantation for prevention of systemic embolism. First experience in the North-West region. Translational Medicine. 2016;3(3):59–66. doi:10.18705/2311-4495-2016-3-3-59-66. (In. Russian)

4. Altiok E., Marx N. Oral Anticoagulation. Dtsch Arztebl Int. 2018 Nov 16;115(46):776-783. doi: 10.3238/arztebl.2018.0776.

5. Guo Y., Lip G.Y., Apostolakis S. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants. Hosp. Pract. (1995). 2013 Feb; 41(1):71-78. doi: 10.3810/hp.2013.02.1012.